Document Detail

Persistent Use of Against-Label Statin-Fibrate Combinations from 2003-2009 Despite United States Food and Drug Administration Dose Restrictions.
MedLine Citation:
PMID:  22570173     Owner:  NLM     Status:  Publisher    
STUDY OBJECTIVE: To describe the prevalence of prescribing against-label statin-fibrate combination therapy. DESIGN: Retrospective cohort study. DATA SOURCE: Medstat MarketScan Commercial Claims and Encounter database. PATIENTS: Adults (aged 18-89 yrs) who were prescribed statin-fibrate combination therapy between January 1, 2003, and June 30, 2009, had pharmacy claims demonstrating two or more concurrently filled prescriptions for a statin and a fibrate, and had continuous insurance enrollment for at least 12 months. MEASUREMENTS AND MAIN RESULTS: Claims data were used to identify patients with dyslipidemia based on International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes. National Drug Codes were used to describe concurrent statin-fibrate combination therapy. The primary outcome was recent use of against-label statin-fibrate combination therapy, defined as use during the last 18 months (January 1, 2008-June 30, 2009) of the study period. Patients were stratified according to statin and dosage to identify against-label combination use (e.g., simvastatin > 10 mg/day with gemfibrozil). Within the recent-use period, 131,394 patients were prescribed concurrent statin-fibrate combination therapy; of these patients, 13,420 (10.2%) had against-label therapy. Simvastatin-gemfibrozil accounted for 8978 (66.9%) of all against-label combinations. Of all 9877 simvastatin-gemfibrozil combinations prescribed in the recent-use period (both on-label and against-label use), 8978 (90.9%) were against label. The secondary outcome was prevalence of against-label statin-fibrate combination therapy on an annual basis: 15.5% in 2003, 18.7% in 2004, 9.1% in 2005, 8.3% in 2006, 9.2% in 2007, and 9.8% in 2008. CONCLUSION: Against-label statin-fibrate combination therapy continues to be prescribed despite established United States Food and Drug Administration (FDA) dose restrictions. Nearly every time the simvastatin-gemfibrozil combination was prescribed, it was against label because simvastatin exceeded the maximum dose restriction. Updated simvastatin labeling in June 2011 includes additional maximum dose restrictions and new contraindications, which include gemfibrozil. Different approaches in clinical practice are needed to ensure adherence with the revised FDA labeling.
Julie C Alford; Joseph J Saseen; Richard R Allen; Kavita V Nair
Related Documents :
20540173 - Effectiveness of premature epidural catheter termination as a quality indicator in a de...
16055803 - Pathways to care for first-episode psychosis in an early detection healthcare sector: p...
24044913 - Calculating the number of shock waves, expulsion time, and optimum stone parameters bas...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-5-8
Journal Detail:
Title:  Pharmacotherapy     Volume:  -     ISSN:  1875-9114     ISO Abbreviation:  -     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-5-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Pharmacotherapy Publications, Inc. All rights reserved.
Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Improved Extraction of Saturated Fatty Acids but not Omega-3 Fatty Acids from Sheep Red Blood Cells ...
Next Document:  The role of nanoscale architecture in supramolecular templating of biomimetic hydroxyapatite mineral...